Diagnostic Criteria and Treatment Options for Myasthenia Gravis (MG)

Diagnostic Criteria

The American Academy of Neurology recommends diagnostic testing for Myasthenia Gravis, including acetylcholine receptor (AChR) and antistriated muscle antibodies in blood, as well as electrodiagnostic studies with repetitive stimulation and/or jitter studies 1
Fatigable or fluctuating muscle weakness, generally more proximal than distal, is a common clinical presentation of Myasthenia Gravis 2
Ocular and/or bulbar involvement, including ptosis, extraocular movement abnormalities, dysphagia, dysarthria, and facial muscle weakness, can occur in patients with Myasthenia Gravis 2
The ice test, which involves applying an ice pack over closed eyes for 2 minutes, is a highly specific test for Myasthenia Gravis, particularly for ocular symptoms 3, 4

Treatment Options

The Myasthenia Gravis Foundation of America recommends a stepwise approach to treatment, starting with pyridostigmine and potentially escalating to immunosuppressive therapy based on disease severity 2
Pyridostigmine, an acetylcholinesterase inhibitor, is typically started at 30 mg orally three times daily and gradually increased to a maximum of 120 mg orally four times daily as tolerated 2
Corticosteroids, such as prednisone, can be used as a second-line treatment for patients with Grade 2 or higher symptoms, with approximately 66-85% of patients showing a positive response 2, 4
Immunosuppressive therapy with azathioprine can be used as a third-line treatment option for patients with moderate to severe disease 4

Important Considerations and Pitfalls

The American Academy of Neurology recommends avoiding certain medications, including β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides, in patients with Myasthenia Gravis due to potential exacerbation of symptoms 2
Regular pulmonary function assessment is crucial in patients with generalized Myasthenia Gravis to monitor for respiratory compromise 2
Collaboration between an experienced ophthalmologist and neurologist is necessary for diagnosis and management of Myasthenia Gravis, particularly in patients with ocular involvement 4

Best Initial Management for Suspected Myasthenia Gravis with Ocular Symptoms

Rationale for Pyridostigmine as First-Line Treatment

The patient's presentation with fatigable weakness of extraocular muscles and ptosis that improves with ice pack application is highly specific for myasthenia gravis, and approximately 50% of patients with ocular myasthenia may show minimal response to pyridostigmine alone, potentially requiring escalation to corticosteroids 5
Regular assessment of respiratory function should continue, as 50-80% of patients with initial ocular symptoms may develop generalized myasthenia within a few years 5

Monitoring and Follow-up

Approximately 50% of patients with ocular myasthenia may show minimal response to pyridostigmine alone, potentially requiring escalation to corticosteroids, according to the American Academy of Ophthalmology 5

Efgartigimod Alfa and Hyaluronidase-qvfc Therapy for Myasthenia Gravis

Alternative Treatment Options

For patients not responding to initial therapy, consideration of plasmapheresis or IVIG (2 g/kg over 5 days) for patients with moderate to severe symptoms is recommended by the Journal of Clinical Oncology 6
Evaluation for thymectomy if appropriate is suggested by Ophthalmology 7

Ongoing Patient Care

Regular pulmonary function assessment is crucial given the patient's reported shortness of breath with light activity, as recommended by the Journal of Clinical Oncology 8

Myasthenia Gravis Diagnosis and Management

Clinical Features and Diagnostic Considerations

Drooling, difficulty climbing stairs, and hoarseness are symptoms that may be present in patients with myasthenia gravis, particularly those with bulbar and facial involvement 9
Any patient with suspected myasthenia gravis requiring surgery must have serum anti-acetylcholine receptor antibody levels measured preoperatively to avoid respiratory failure during anesthesia 9
Approximately 30-50% of patients with thymomas have myasthenia gravis, and all patients suspected of having thymomas should have serum anti-acetylcholine receptor antibody levels measured before any surgical procedure 9
In approximately 20% of thymoma patients, mortality is related to myasthenia gravis 9

Pupil Involvement in Myasthenia Gravis

Key Diagnostic Features

Pupils are characteristically not affected in myasthenia gravis, which serves as an important distinguishing feature from other causes of ophthalmoplegia and ptosis, as emphasized by the American Academy of Ophthalmology 10, 11, 12
The presence of pupillary involvement should immediately alert the clinician to carefully consider other etiologies, particularly third nerve palsy, according to the American Academy of Ophthalmology guidelines 10, 11

Pathophysiologic Basis

Myasthenia affects the neuromuscular junction of voluntary skeletal muscles, not the autonomic nervous system, which explains the pupil-sparing pattern in myasthenia gravis 12, 11
Acetylcholine receptor antibodies target nicotinic receptors at the neuromuscular junction of extraocular muscles, levator palpebrae, and orbicularis oculi, but not the autonomic nervous system responsible for pupillary function 12, 11
Pupillary function depends on autonomic innervation (parasympathetic and sympathetic), which operates through different receptor systems not affected by the autoimmune process in myasthenia 12, 11

Practical Diagnostic Approach

Immediately assess pupillary function as part of the initial examination in patients with ptosis and ophthalmoplegia, as recommended by the American Academy of Ophthalmology 10, 11
If pupils are abnormal, prioritize evaluation for third nerve palsy, Horner syndrome, or other neurologic causes over myasthenia gravis, according to the American Academy of Ophthalmology guidelines 10, 11

Differential Diagnosis for Ocular Myasthenia Gravis

Key Distinguishing Features

The American Academy of Ophthalmology notes that the differential diagnosis for ocular myasthenia gravis includes any pupil-sparing ocular motility disorder, with the most critical distinctions being third nerve palsy, thyroid eye disease, chronic progressive external ophthalmoplegia, Lambert-Eaton syndrome, botulism, brainstem lesions, and orbital pathology 13, 14

Primary Differential Diagnoses

The American Academy of Ophthalmology recommends that third nerve palsy be distinguished from ocular myasthenia gravis, as it can present with ptosis and ophthalmoplegia but typically involves pupillary abnormalities, and requires immediate neuroimaging and vascular workup given risk of aneurysm or ischemia 14
The American Thyroid Association notes that thyroid eye disease causes restrictive myopathy with mechanical limitation rather than neuromuscular junction dysfunction, with key distinguishing features including proptosis, eyelid retraction, and fixation duress, and forced duction testing confirms mechanical restriction in TED versus fatigable weakness in myasthenia 15
The American Academy of Ophthalmology states that orbital imaging shows tendon-sparing muscle enlargement in thyroid eye disease, which distinguishes it from myasthenia 15

Diagnostic Approach to Differentiate

The American Academy of Ophthalmology recommends that anti-AChR antibodies be tested, as they are present in only 40-77% of ocular myasthenia, and single-fiber EMG has >90% sensitivity for ocular myasthenia 13
The American College of Radiology notes that orbital CT/MRI differentiates thyroid eye disease (tendon-sparing muscle enlargement) from myasthenia 15

Prognosis and Management

The American Academy of Ophthalmology warns that approximately 50-80% of patients presenting with isolated ocular symptoms will develop generalized myasthenia within a few years, making accurate diagnosis essential for preventing life-threatening respiratory failure 13, 14

Diagnosis and Management of Myasthenia Gravis

Diagnostic Testing and Differential Diagnoses

The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, suggests that botulism can be differentiated from myasthenia gravis by considering symmetric cranial nerve palsies and gastrointestinal symptoms 16
The MMWR Recommendations and Reports guidelines indicate that standard EMG and nerve conduction studies may be normal early in the disease course, and electrodiagnostic studies are operator-dependent, requiring specialized equipment and expertise 16
According to MMWR Recommendations and Reports, cerebrospinal fluid examination is typically normal in myasthenia gravis, which helps distinguish it from Guillain-Barré syndrome where CSF protein is often elevated by week 2 16
Brain imaging, as recommended by MMWR Recommendations and Reports, may help exclude brainstem strokes that can mimic myasthenia gravis 16

Myasthenia Gravis Classification and Treatment

Classification Systems

The Myasthenia Gravis Foundation of America (MGFA) classifies myasthenia gravis into five classes based on severity: Class I (ocular symptoms only), Class II (mild generalized weakness), Class III (moderate generalized weakness), Class IV (severe generalized weakness), and Class V (myasthenic crisis requiring intubation), which guides treatment decisions 17

Treatment Algorithm

For MGFA Class I-II, the American College of Neurology recommends first-line treatment with pyridostigmine 30 mg orally three times daily, gradually increasing to maximum 120 mg orally four times daily as tolerated, and second-line treatment with corticosteroids (prednisone 1-1.5 mg/kg orally daily) if symptoms persist despite pyridostigmine 17
For MGFA Class III-V, the American College of Neurology recommends immediate actions including permanently discontinuing any causative immune checkpoint inhibitors, admitting the patient with ICU-level monitoring capability, and obtaining urgent neurology consultation, as well as acute treatment with corticosteroids, IVIG, or plasmapheresis 17

Diagnostic Considerations

The American Academy of Neurology recommends comprehensive evaluation for all grades of myasthenia gravis, including serologic testing, electrodiagnostic studies, imaging, cardiac evaluation, and neuroimaging, to rule out concurrent conditions and alternative diagnoses 17

Prognosis

Myasthenic crisis (Class V) is life-threatening and requires immediate ventilatory support and aggressive immunotherapy, according to the Myasthenia Gravis Foundation of America 17

Myasthenia Gravis Management

Diagnostic Evaluation

The American College of Cardiology recommends checking troponin to evaluate for myocardial involvement in patients with myasthenia gravis, as cardiac involvement requires permanent discontinuation of certain immunotherapies 18

Treatment Algorithm

The American College of Clinical Oncology suggests that prednisone 1-1.5 mg/kg orally daily can be added as a second-line treatment for patients with mild disease who have an inadequate response to pyridostigmine, and this dose can be tapered gradually based on symptom improvement 18
The American College of Clinical Oncology recommends initiating combination therapy with pyridostigmine and prednisone 1-1.5 mg/kg orally daily for patients with moderate to severe disease 18

Diagnostic and Prognostic Indicators for Ocular Myasthenia Gravis

Serological Testing

In patients with suspected ocular myasthenia gravis who have negative single‑fiber EMG and negative anti‑acetylcholine receptor (AChR) antibodies, anti‑muscle‑specific kinase (MuSK) antibodies should be ordered because approximately one‑third of seronegative cases are MuSK‑positive. 19
Anti‑lipoprotein‑related protein 4 (LRP4) antibodies are also associated with both generalized and ocular myasthenia gravis and may be considered in the serologic work‑up. 19
About 50 % of individuals with purely ocular myasthenia gravis are seronegative for AChR antibodies; therefore a negative AChR result does not exclude the diagnosis. 19

Electrophysiologic Testing

Single‑fiber electromyography (SFEMG) has a sensitivity greater than 90 % for ocular myasthenia gravis and is regarded as the gold‑standard test; a negative SFEMG result is therefore atypical and warrants careful reconsideration of the differential diagnosis. 19

Bedside Clinical Tests

Ice‑pack test – Apply an ice pack over closed eyes for ~2 minutes (ptosis) or ~5 minutes (strabismus); a reduction of ptosis of roughly 2 mm or improvement in ocular alignment supports myasthenia gravis. The test is highly specific for the disease. 19
Rest test (without ice) can also provide supportive diagnostic information. 19

Pharmacologic Testing

The edrophonium (Tensilon) test may be employed by experienced clinicians; it demonstrates a sensitivity of 86 % for ocular myasthenia gravis. The test must be performed in a monitored setting with atropine (0.4–0.5 mg IV) readily available to treat potential muscarinic side effects (e.g., excessive tearing, salivation, sweating, bradycardia, bronchospasm, hypotension, syncope). 19

Therapeutic Trial

An empiric trial of pyridostigmine (starting at 30 mg orally three times daily) can serve both diagnostic and therapeutic purposes; however, roughly 50 % of ocular myasthenia patients exhibit minimal response to pyridostigmine alone, which does not rule out the diagnosis. 19

Prognosis and Monitoring

Between 50 % and 80 % of patients who initially present with ocular symptoms progress to generalized myasthenia gravis within a few years, most commonly within the first two years after onset. 19

Dysphagia as a High‑Risk Feature in Myasthenic Crisis

High‑Risk Patient Populations

In patients with myasthenia gravis, oropharyngeal and bulbar weakness—especially dysphagia—are present in more than 50 % of cases that precede a myasthenic crisis, highlighting dysphagia as a key early warning sign for impending respiratory failure. 20

Ice Pack Test for Myasthenia Gravis Diagnosis

Procedure

Interpretation Criteria

Physiologic Basis

Clinical Indications

Alternative Bedside Test

Prognostic Implications

Management of Myasthenic Crisis: Respiratory Assessment and ICU Admission

Respiratory Assessment Indicators

In patients with known myasthenia gravis who present with dyspnea, an inability to count to 15 on a single breath is a reliable clinical marker of imminent respiratory insufficiency and should prompt urgent evaluation for myasthenic crisis. 22

Cough Effectiveness

Diminished cough strength and ineffective clearance of secretions in myasthenia gravis patients constitute a key indication for intensive‑care unit (ICU) admission, as poor cough reflex increases the risk of aspiration and respiratory failure. 22

ICU Admission Timing and Mechanical Ventilation Outcomes

Among myasthenic crisis patients, the median duration of mechanical ventilation is 12–14 days; approximately 22 % require ventilation within the first week of crisis onset. Early recognition and prompt ICU transfer are associated with reduced mortality. 22

Diagnostic Workup Recommendations for Myasthenia Gravis

Serologic Panel

Anti‑striated muscle antibodies should be included in the initial serologic panel for myasthenia gravis. 23

Electrodiagnostic Evaluation

Nerve conduction studies and needle electromyography should be performed to exclude peripheral neuropathy and to assess for concurrent myositis. 23

Respiratory and Cardiac Assessment

Pulmonary function testing—including negative inspiratory force and vital capacity—is essential to evaluate respiratory muscle involvement, because dysphagia and bulbar weakness precede myasthenic crisis in > 50 % of patients. 23
Cardiac evaluation with troponin measurement, electrocardiogram, and, when indicated, transthoracic echocardiography or cardiac MRI should be undertaken to rule out myocarditis, especially in the presence of respiratory insufficiency or elevated muscle enzymes. 23

Laboratory Screening for Myositis

Serum creatine kinase, aldolase, erythrocyte sedimentation rate, and C‑reactive protein should be measured to screen for possible concurrent myositis. 23

Neuro‑Imaging

Brain and/or spine magnetic resonance imaging should be considered according to clinical symptoms to exclude central nervous system lesions that could mimic myasthenia gravis. 23

Medication Review

All medications known to exacerbate myasthenia gravis—such as β‑blockers, intravenous magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics—should be promptly identified and discontinued. 23

Diagnostic Workup and Ancillary Testing for Myasthenia Gravis

Serologic Panel Enhancements

Adding anti‑striated muscle antibodies to the initial serologic panel helps identify patients at higher risk for thymoma. 24

Electrodiagnostic Adjuncts

Performing nerve conduction studies and needle electromyography alongside repetitive nerve stimulation aids in excluding peripheral neuropathy and detecting concurrent myositis. 24

Pharmacologic Precautions for Edrophonium Testing

Atropine (0.4–0.5 mg IV) must be immediately available during edrophonium (Tensilon) testing to treat potential muscarinic side‑effects such as excessive tearing, salivation, bradycardia, or bronchospasm. 24

Respiratory and Cardiac Assessment

Dysphagia and bulbar weakness precede myasthenic crisis in more than 50 % of cases, underscoring the need for pulmonary function testing (negative inspiratory force and vital capacity) to evaluate respiratory muscle involvement. 24
Evaluation for concomitant myocarditis should include troponin T measurement, electrocardiography, and consideration of transthoracic echocardiography when respiratory insufficiency or elevated creatine kinase is present. 24

Myositis Screening

Laboratory screening for possible concurrent myositis should include creatine phosphokinase, aldolase, erythrocyte sedimentation rate, and C‑reactive protein. 24

Neuroimaging Recommendations

Brain and/or spinal magnetic resonance imaging should be considered based on clinical symptoms to exclude central nervous system lesions that could mimic myasthenia gravis. 24

Medication Management

Medications known to exacerbate myasthenia gravis—β‑blockers, intravenous magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics—should be identified and discontinued promptly. 24